Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions
April 5, 2018
Food Quality & Safety
Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions.
Beaver said the change will make it more challenging for the FDA to pursue violations, especially where the agency has chosen to issue guidance documents rather than set rules. He also pointed out that one of the first steps the Trump administration took was an executive action that requires agencies to eliminate two rules for every new rule they finalize. Given that, he said, the FDA is likely to continue to avoid rulemaking except where absolutely necessary.
Beaver said the change will make it more challenging for the FDA to pursue violations, especially where the agency has chosen to issue guidance documents rather than set rules. He also pointed out that one of the first steps the Trump administration took was an executive action that requires agencies to eliminate two rules for every new rule they finalize. Given that, he said, the FDA is likely to continue to avoid rulemaking except where absolutely necessary.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“